: New therapies for malaria are urgently needed. Combination therapy for uncomplicated malaria appears to offer the best opportunity for effective therapy and for the prevention of selection of resistant parasites. However, it is not clear how best to compare the efficacies of antimalarial regimens. Recent results from our group and others suggest that traditional short-term evaluations of efficacy are not adequate to most appropriately compare different regimens. Rather, important differences may only be apparent after long-term evaluation. Longitudinal evaluation also provides a """"""""real world"""""""" comparison of different regimens, with assessments of the effects of repeated dosing on malarial incidence, selection of resistant parasites, and drug toxicity. New molecular techniques allow improvements in longitudinal studies, by providing accurate assessment of treatment responses. They can also help to characterize the roles of parasite and host polymorphisms in disease incidence and responses to therapy. We hypothesize that longitudinal evaluation will identify important differences between the efficacies and selective pressures of leading antimalarial combination therapies; even if short-term activities are similar. We further hypothesize that identifiable parasite and host polymorphisms will help predict outcomes after antimalarial therapy and that the characterization of these polymorphisms will identify factors that contribute to responses to therapy. This project is designed to test these hypotheses through a longitudinal comparison of four combination therapies for uncomplicated malaria and the performance of related molecular studies to characterize the parasite and host factors that impact upon disease. The project will include clinical studies at our study site in Kampala, Uganda and related biochemistry and molecular studies in Kampala and San Francisco.
Our specific aims will be (1) to compare the efficacies of combination antimalarial therapies using a longitudinal design, (2) to follow plasmodia genetic polymorphisms as longitudinal markers of antimalarial drug resistance, and (3) to evaluate the roles of host genetic polymorphisms in antimalarial drug resistance and the incidence of clinical malaria. We anticipate that the experiments designed to achieve these aims will contribute to improved management of malaria and to a better understanding of the genetic factors that impact upon responses to therapy for this disease. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI052142-03
Application #
6879940
Study Section
Tropical Medicine and Parasitology Study Section (TMP)
Program Officer
Coyne, Philip Edward
Project Start
2003-08-15
Project End
2008-02-29
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
3
Fiscal Year
2005
Total Cost
$912,880
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Gantt, Soren; Huang, Meei-Li; Magaret, Amalia et al. (2013) An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia. J Clin Virol 58:276-8
Yeka, Adoke; Gasasira, Anne; Mpimbaza, Arthur et al. (2012) Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop 121:184-95
Ruel, Theodore D; Boivin, Michael J; Boal, Hannah E et al. (2012) Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis 54:1001-9
Gupta, Vinay; Perez-Perez, Guillermo I; Dorsey, Grant et al. (2012) The seroprevalence of Helicobacter pylori and its relationship to malaria in Ugandan children. Trans R Soc Trop Med Hyg 106:35-42
Baliraine, Frederick N; Rosenthal, Philip J (2011) Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis 204:1120-4
Greenhouse, Bryan; Ho, Benjamin; Hubbard, Alan et al. (2011) Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis 204:19-26
Baliraine, Frederick N; Nsobya, Samuel L; Achan, Jane et al. (2011) Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda. Antimicrob Agents Chemother 55:615-22
Clark, Tamara D; Njama-Meya, Denise; Nzarubara, Bridget et al. (2010) Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS One 5:e11759
Gasasira, Anne F; Kamya, Moses R; Ochong, Edwin O et al. (2010) Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J 9:177
Nsobya, Samuel L; Kiggundu, Moses; Nanyunja, Sarah et al. (2010) In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 54:1200-6

Showing the most recent 10 out of 29 publications